你即將離開本站

並前往https://www.investing.com/analysis/abbvie-has-a-mixed-outlook-after-mixed-earnings-200635262

AbbVie Has a Mixed Outlook After Mixed Earnings

The story for ABBV stock will come down to how much erosion it expects as it loses U.S. patent protection on Humira.

確定！ 回上一頁

查詢 「Humira stock」的人也找了：

  1. AbbVie
    2.
  2. Amgen stock
    3.
  3. Adm stock
    4.
  4. abbvie產品
    5.
  5. MO stock
    6.
  6. BMY stock
    7.
  7. Novartis stock
    8.
  8. J.P. stock
    9.